Q-omics provides the consensus-scored CABYR profile across patient tissues and cancer cell-line models. CABYR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CABYR is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CABYR RNA expression shows 20,221 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where CABYR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CABYR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CABYR survival associations across molecular data types. CABYR RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CABYR RNA expression–survival associations across cancer types. High CABYR expression shows unfavorable associations in MESO, UVM, KIRC, LIHC, ACC and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CABYR RNA expression.
This table summarizes CABYR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CABYR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CABYR shows higher tumor expression in KIRC, LUAD, LUSC, HNSC, KIRP and COAD. The KIRC box plot shows higher CABYR RNA expression in tumor versus normal tissue (log2 FC = +0.458, t-test p < 0.001).
This table shows molecular features associated with CABYR in patient tissues and cancer cell lines. In patient samples, CABYR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CABYR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
